# PolyCore Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/polycore-therapeutics

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.polycoretherapeutics.com
- Total disclosed funding: $5M
- Latest round: Seed (Apr 11, 2022)
- Investors on record: 2

## About

Based in Pennsylvania, US, and founded in 2014 by Jim Harris, PolyCore Therapeutics, LLC operates as a biopharmaceutical company that develops treatments for patients with neurodegenerative diseases. In April 2022, PolyCore Therapeutics, LLC, led by its CEO Kelly Beck, raised an amount of USD 4.71 million in seed funding from new investor Xontogeny, LCC, and returning investor Ben Franklin Technology Partners.

The firm's product pipeline includes PCT-3012, a novel small molecule for the treatment of Parkinson’s motor symptoms and dyskinesia in patients with early- to mid-stage Parkinson’s Disease.  In addition, the company is looking into PCT-3012's potential uses for the treatment of ADHD, Huntington’s disease, and other dyskinesia and cognitive disorders.

The company intends to use the funds raised in April 2022 to further study and investigate the application of the drug and to move for human clinical trials.

## Funding rounds

- Seed, Apr 11, 2022, $4.7M — Ben Franklin Technology Partners, Xontogeny, LLC
- Seed, Jun 22, 2016, $0.3M — Ben Franklin Technology Partners

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Seed
- Xontogeny, LLC — Seed